Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs  40k   105   22

398.75
+37.70 (10.44%)
NSE: Today, 03:58 PM

Price Summary

Today's High

₹ 408.5

Today's Low

₹ 362.95

52 Week High

₹ 392

52 Week Low

₹ 268.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3600.82 Cr.

Enterprise Value

4831.01 Cr.

No. of Shares

9.03 Cr.

P/E

769.05

P/B

1.04

Face Value

₹ 10

Div. Yield

0.38 %

Book Value (TTM)

₹  382.61

CASH

14.45 Cr.

DEBT

1244.63 Cr.

Promoter Holding

28.27 %

EPS (TTM)

₹  0.52

Sales Growth

6.54%

ROE

5.42 %

ROCE

2.18%

Profit Growth

130.3 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.54%
3 Year8.78%
5 Year7.45%

Profit Growth

1 Year130.3%
3 Year17.75%
5 Year10.67%

ROE%

1 Year5.42%
3 Year3.87%
5 Year4.02%

ROCE %

1 Year2.18%
3 Year3.85%
5 Year4.31%

Debt/Equity

0.3656

Price to Cash Flow

-12.74

Interest Cover Ratio

1.28970514944572

CFO/PAT (5 Yr. Avg.)

0.374517558782008

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 28.27 81.8
Dec 2022 30.89 69.44
Sep 2022 31.07 69.42
Jun 2022 30.37 62.2
Mar 2022 30.6 56.67
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 16.3466705484464% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 77.701720952145 days.

 Limitations

  • The company has shown a poor revenue growth of 8.78014010271246% for the Past 3 years.
  • Company has a poor ROE of 3.87493173323265% over the past 3 years.
  • Promoter pledging has increased from 28.27% to 81.8% in 1 quarter.
  • Company has a poor ROCE of 3.8547124418507% over the past 3 years
  • Company has high debtor days of 195.316571020863.
  • Company has contingent liabilities of 2330.962 Cr.
  • Company has negative cash flow from operations of -282.685.
  • Tax rate is low at -737.771991816998.
  • Promoter pledging is high as 81.8%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 455.66 423.19 481.24 386.51 563.56
Total Expenditure 437.82 484.22 486.77 340.91 444.12
Operating Profit 17.83 -61.03 -5.53 45.61 119.44
Other Income 84.83 7.47 20.47 29.75 26.38
Interest 21.55 26.02 34.66 35.1 42.9
Depreciation 24.41 24.3 24.35 22.26 22.71
Exceptional Items 0 0 0 0 -15
Profit Before Tax 56.71 -103.88 -44.07 17.99 65.2
Tax -143.8 -37.63 -40.07 5.46 2.8
Profit After Tax 200.5 -66.25 -4 12.54 62.4
Adjusted EPS (Rs) 22.33 -7.38 -0.44 1.39 6.91

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 1469.61 1537.44 1691.93 1857.57 1979
Total Expenditure 1272.52 1398.39 1487.48 1698.34 1902.37
Operating Profit 197.09 139.04 204.46 159.23 76.63
Other Income 156.2 114.61 93.07 117.09 123.49
Interest 81.97 54.09 66.84 65.34 74.24
Depreciation 77.81 83 94.24 99.34 104.37
Exceptional Items -29.38 -3.52 0 0 0
Profit Before Tax 164.13 113.03 136.45 111.64 21.51
Tax 7.69 -1.38 16.17 33.4 -158.68
Net Profit 891.59 110.37 120.28 78.24 180.19
Adjusted EPS (Rs.) 17.48 12.78 13.43 8.72 20.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 89.5 89.55 89.57 89.68 89.79
Total Reserves 3072.52 3167.25 3069.22 3158.38 3316.89
Borrowings 2.45 0.15 0 147.54 124.7
Other N/C liabilities -36.86 -63.27 -37.31 159.89 -16.42
Current liabilities 1104.05 1388.99 1454.95 1590.64 1841.32
Total Liabilities 4231.65 4582.68 4576.42 5146.12 5356.28
Assets
Net Block 497.96 496.73 578.35 576.66 604.09
Capital WIP 86.89 72.56 89.47 81.36 30.45
Intangible WIP 56.97 49.9 22.78 29.31 25.26
Investments 1465.19 1994.59 2170.55 2394.65 2399.76
Loans & Advances 154.76 223.27 237.29 247.33 304.95
Other N/C Assets 507.41 82.04 83.95 72.96 16.51
Current Assets 1462.48 1663.59 1394.03 1743.86 1975.25
Total Assets 4231.65 4582.68 4576.42 5146.12 5356.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 915.8 108.33 136.45 111.64 21.51
Adjustment -670.77 90.19 130.28 114.15 75.17
Changes in Assets & Liabilities -161.75 -121.04 -96.91 -109.81 -400.77
Tax Paid -17.68 -37.52 -32.18 166.79 21.41
Operating Cash Flow 65.59 39.97 137.64 282.76 -282.69
Investing Cash Flow 432.96 -166.06 62.83 -275.64 18.78
Financing Cash Flow -706.77 123.26 -203.56 -48.64 250.73
Net Cash Flow -208.22 -2.83 -3.09 -41.52 -13.18

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 30.60 30.37 31.07 30.89 28.27
pronomz ventures l... 14.14 14.14 14.14 14.14 14.14
sequent scientific... 3.70 3.70 3.70 3.70 3.70
arun kumar pillai 1.53 1.53 1.53 1.53 1.53
abusha investment ... 0.31 0.31 0.31 0.31 0.31
karuna business so... 0.67 0.67 0.67 0.67 0.67
lifecell internati... 1.56 - 1.56 1.56 1.56
k r ravishankar 1.40 1.40 1.40 1.40 1.40
devendra estates l... 1.23 0.92 0.92 0.92 0.92
shasun leasing and... 1.08 1.12 1.12 1.12 1.12
devendra estates p... - - - - -
rupali jatin 0.22 0.21 0.21 0.21 0.21
vimal kumar s 0.30 0.29 0.29 0.29 0.29
monisha nitin 0.18 0.16 0.16 0.16 0.16
leela v 0.47 0.47 0.47 0.47 0.47
nitin kumar v 0.48 0.56 0.56 0.56 0.56
ambemata securities 0.54 0.54 0.54 0.54 0.54
jatin v 0.44 0.51 0.51 0.51 0.51
chaitanya d 0.37 0.47 0.47 0.47 0.47
chayadeep properti... 0.46 0.46 0.46 0.46 0.46
jitesh d 0.41 0.41 0.41 0.41 0.41
sajjan d 0.18 0.19 0.18 0.19 0.19
aditya arun kumar - - - - -
tarini arun kumar - - - - -
deepa arun kumar - - - - -
padmakumar karunak... 0.19 0.19 0.19 0.19 0.19
vineetha mohanakum... 0.20 0.20 0.20 0.20 0.20
devendra kumar s 0.01 0.01 0.01 0.01 0.01
k r lakshmi 0.15 0.15 0.15 0.15 0.15
vimal kumar s - (... 0.13 0.13 0.13 0.13 0.13
agnus holdings pvt... 0.13 0.13 0.13 0.13 0.13
vimal kumar s - h... - - - - -
sajitha pillai 0.09 0.09 0.09 0.09 0.09
suchi chaitanya sr... 0.10 0.10 0.10 0.10 0.10
pooja srisrimal 0.10 0.10 0.10 0.10 0.10
rajeswari amma 0.10 0.10 0.10 0.10 0.10
s abhaya kumar huf - 0.07 0.07 0.07 0.07
rajitha gopalakris... 0.05 0.05 0.05 0.05 0.05
hemalatha pillai 0.05 0.05 0.05 0.05 0.05
lakshmi gopalakris... 0.06 0.06 0.06 0.06 0.06
gayatri nair 0.04 0.04 0.04 0.04 0.04
purushothaman pill... 0.04 0.04 0.04 0.04 0.04
triumph venture ho... 0.04 0.04 0.04 0.04 0.04
agnus capital llp 0.02 0.02 0.02 0.02 0.02
karuna ventures pr... 0.02 0.02 0.02 0.02 0.02
vibha srisrimal - 0.02 0.02 0.02 0.02
taru mardia - 0.02 0.02 0.02 0.02
rahul nair 0.02 0.02 0.02 0.02 0.02
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 69.40 69.63 68.93 69.11 71.73
sbi arbitrage oppo... - - - - -
sbi large & midcap... 8.84 - - - -
sbi magnum taxgain... - - 7.89 6.98 -
sbi long term equi... - 7.31 - - 7.60
sbi magnum multipl... - - - - -
aditya birla sun l... - - 5.05 - -
aditya birla sun l... - 6.96 - - 6.20
aditya birla sun l... 6.66 - - 5.50 -
aditya birla sun l... - - - - -
life insurance cor... 3.63 3.63 3.63 3.63 3.63
route one offshore... - 4.47 - - -
route one offshore... 4.13 - 4.22 4.33 4.47
bnp paribas arbitr... 3.75 2.70 3.05 3.22 3.27
government pension... 3.16 3.45 3.45 3.45 3.45
route one fund i, ... 2.93 3.00 2.83 2.90 3.00
dsp equity & bond ... 2.91 - 2.91 2.55 -
dsp blackrock equi... - - - - -
karst peak asia ma... - - - - -
brookdale mauritiu... 1.27 1.55 1.81 2.26 2.04
hdfc trustee compa... - - - - -
hdfc trustee compa... - - - - -
uti - core equity ... - - - - -
uti captial protec... - - - - -
db international (... - - - - -
kotak small cap fu... - - - - -
hdfc trustee compa... - - - - -
morgan stanley mau... - - - - -
satpal khattar 1.74 1.74 1.74 1.74 1.74
msd india fund ltd - - - - -
karst peak vermili... - - - - -
apax global alpha ... 1.47 - 1.47 1.47 -
kotak equity savin... - - - - -
sundaram mutual fu... - - - - -
kotak midcap - - - - -
hdfc trustee compa... 1.25 1.25 1.25 1.25 1.25
morgan stanley asi... - - - - 1.19
msd india fund,ltd - - - - -
suresh kumar agarw... - - 1.01 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Strides Pharma Science informs about earnings call transcript1 Jun 2023, 3:09PM Strides Pharma Scien - Quaterly Results25 May 2023, 2:20PM Strides Pharma Scien - Quaterly Results25 May 2023, 2:20PM Strides Pharma Science India informs about updates 19 May 2023, 9:38AM Strides Pharma Science gets EIR from USFDA for Puducherry manufacturing facility19 May 2023, 9:14AM Strides Pharma Science informs about press release3 May 2023, 9:39AM Strides Pharma Science enters into strategic partnership with Orbicular3 May 2023, 9:26AM Strides Pharma Science informs about disclosure23 Mar 2023, 1:59PM USFDA issues EIR to Strides Pharma Science’s Bangalore facility 24 Feb 2023, 11:38AM Strides Pharma Science informs about press release24 Feb 2023, 9:50AM Strides Pharma Science informs about press release21 Feb 2023, 3:29PM Strides Pharma Science informs about audio recording of earnings call25 Jan 2023, 11:46AM Strides Pharma Science informs about grant of options under ESOP 24 Jan 2023, 5:12PM Strides Pharma Science informs about outcome of board meeting24 Jan 2023, 5:09PM Strides Pharma Scien - Quaterly Results24 Jan 2023, 2:41PM Strides Pharma Scien - Quaterly Results24 Jan 2023, 2:41PM Strides Pharma Scien - Quaterly Results24 Jan 2023, 2:41PM Strides Pharma Science’s arm receives EIR from USFDA18 Jan 2023, 3:29PM Strides Pharma Science informs about press release18 Jan 2023, 12:23PM Strides Pharma Science’s arm’s CDMO partner gets nod for key ANDA from USFDA28 Dec 2022, 2:59PM Strides Pharma Science’s arm gets AUD 94 million as deferred consideration for sale of Australian operations 22 Dec 2022, 11:38AM Strides Pharma Science informs about press release22 Dec 2022, 11:34AM Strides Pharma Science informs about earnings call transcript22 Nov 2022, 11:26AM Strides Pharma Science’s arm gets USFDA approval for Potassium Chloride Oral Solution18 Nov 2022, 2:25PM Strides Pharma Scien - Quaterly Results14 Nov 2022, 3:17PM Strides Pharma Scien - Quaterly Results14 Nov 2022, 3:17PM Strides Pharma Scien - Quaterly Results14 Nov 2022, 3:17PM Strides Pharma Science informs about press release14 Nov 2022, 9:15AM Strides Pharma Science informs about earnings call 11 Nov 2022, 5:04PM Strides Pharma Science informs about details of loss of certificate 15 Sep 2022, 3:58PM Strides Pharma Science informs about allotment 8 Sep 2022, 10:32AM Strides Pharma Science informs about press release1 Sep 2022, 9:46AM Strides Pharma's arm receives EIR from USFDA for Drug Products facility in Bengaluru 1 Sep 2022, 9:27AM Strides Pharma Science’s arm recalls 1,032 bottles of Prednisone tablets22 Aug 2022, 9:38AM Strides Pharma Science informs about AGM18 Aug 2022, 4:55PM Strides Pharma Science informs about press release18 Aug 2022, 4:21PM Strides Pharma Science’s arm receives USFDA approval for Naproxen Sodium OTC Softgel Capsules18 Aug 2022, 3:17PM Strides Pharma Science informs about disclosure10 Aug 2022, 4:52PM Strides Pharma Science informs about disclosure9 Aug 2022, 4:03PM USFDA completes inspection at Strides Pharma Science's Singapore facility9 Aug 2022, 12:40PM Strides Pharma Science informs about press release3 Aug 2022, 4:44PM Strides Pharma's arm gets USFDA’s approval for Cyclosporine Softgel Capsules3 Aug 2022, 2:30PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Scien - Quaterly Results29 Jul 2022, 1:11PM Strides Pharma Science gets nod to raise Rs 150 crore via NCDs26 Jul 2022, 9:09AM Strides Pharma Science to raise funds through NCDs21 Jul 2022, 11:52AM Strides Pharma Science informs about disclosure8 Jul 2022, 9:52AM Strides Pharma Science informs about press release24 Jun 2022, 11:58AM Strides Pharma Science’s arm gets EU-GMP compliance certificate for two manufacturing facilities16 Jun 2022, 10:57AM

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -282.685 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.3656 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was 130.020746650161 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 3.87215178552028 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 5.42116975393561 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Strides Pharma Scien

X